http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1108906-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-099 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-10 |
| filingDate | 1965-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1968-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1108906-A |
| titleOfInvention | Antigen preparation and vaccine |
| abstract | B. pertussis cells, are grown on a suitable conventional medium, are harvested by centrifugation, resuspended in cold distilled water, and then ruptured by explosive decompression in a cell fractionater by extrusion under a pressure of 15,000 to 50,000 p.s.i., through a small orifice, into a decompression chamber containing low-pressure nitrogen at 20 DEG C. or less. The cells may also be ruptured by sonic oscillation or a mechanical mill. The cell fractionater is sterilized before use by ethylene oxide gas and b -propiolactone. The cellular material is drained into a cooled receiver, and cell wall material sedimented by centrifugation, washed free from cell contents, and treated with deoxycholic acid solution to prepare a vaccine. The initial whole cell harvest may be stored before use, after freezing, freeze drying, or being killed with thimerosal.ALSO:Antigenic material, for use in preparation of vaccine for B pertussis, is extracted from isolated B. pertussis cell wall material by treatment with a solution of sufficient deoxycholic acid salt to give a final concentration of 0.1 to 10% wt./vol., at 2 to 5 DEG C. and alkaline pH of a cell wall suspension equivalent to 100 to 2000 bacteria/ml. The cells may be grown on conventional media, and ruptured mechanically, (see Division C6), and are then washed free from cellular material, extracted as above, the deoxycholate removed by, e.g. dialysis ion exchange, or ultra-filtration, and the solution used to prepare vaccines. These may be mono- or polyvalent, the latter containing toxoids such as Tetanus or Diptheria toxoid, or may be adsorbed onto adjuvants such as aluminium hydroxide or phosphate, or precipitated with alum. The vaccines may contain preservatives such as thimerosal, benzethonium chloride, benzyl alcohol, or g -picolonium chloride. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2135190-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-3043291-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0004137-A1 |
| priorityDate | 1964-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.